Modern possibilities of drug therapy for early and locally advanced triple negative breast cancer

Read full text Summarise with VIRAT
Authors: Анна Сергеевна Белохвостова, Анастасия Борисовна Галицына, Александр Александрович Софийчук, Natalia A. Falaleeva, A. I.A. Abdulkhalim
Cited by: 0
References: 26

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Triple negative breast cancer remains the subtype of breast cancer with the highest rates of recurrence and mortality. Research in the field of tumor biology has led to identification of subgroups of patients with specific molecular features, which has led to the development and approval of many new targeted treatments for this disease. This review considers current options for the treatment of locally advanced forms of breast cancer at the neoadjuvant stage – the use of carboplatin, targeted therapy with vascular endothelial growth factor inhibitors and immunotherapy. It discusses the practical problems and unanswered questions that arise in connection with the approval of neoadjuvant immunotherapy, and describes the approach used in the clinical practice to use various treatment options and the possibility of combining them to achieve the best early and long-term results.

Fields of Study & Subjects

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies MRI in cancer diagnosis

Publication details

Journal / source
MD-Onco
Volume
6
Issue
1
Pages
14–23
Publication date
8 April 2026
Language
EN